This activity was planned in collaboration by the Elsevier Office of Continuing Medical Education and ASiM. Thank you for your participation. All information provided improves the scope and purpose of our programs.

You must complete this evaluation form to receive acknowledgement for completing this activity.

*
*
*
*
*
*
*
Please use the scale: 1=Poor, 2=Fair, 3=Good, 4=Very good, 5=Excellent
12345
DESCRIBE the latest evidence providing rationale for targeting the immune system in the treatment of GBM.
EVALUATE results of ongoing clinical trials examining immunotherapy agents as part of GBM treatment paradigms.
RECOGNIZE strategies to manage the unique adverse events related to the use of immunotherapy in GBM.
*
Please use the scale: 1=Never, 2=Rarely, 3=Sometimes, 4=Most of the time, 5=Always, N/A=Not applicable for me
12345N/A
Consider immunotherapy in your patients with GBM.
Combine checkpoint inhibitors with other forms of treatment to create individualized treatment plans for patients with GBM.
Consider the adverse effects of immunotherapy when designing treatment programs for your patients with GBM.
*
Please use the scale: 1=Never, 2=Rarely, 3=Sometimes, 4=Most of the time, 5=Always, N/A=Not applicable for me
12345N/A
Consider immunotherapy in your patients with GBM.
Combine checkpoint inhibitors with other forms of treatment to create individualized treatment plans for patients with GBM.
Consider the adverse effects of immunotherapy when designing treatment programs for your patients with GBM.
*
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Overall, the activity met my learning needs.
The information presented was without promotional or commercial bias.
Was scientifically rigorous and evidence based.
Provided appropriate and effective opportunities for active learning (e.g., discussion, Q & A).
Promoted improvements or quality in healthcare.
The quality of the educational process was satisfactory and appropriate.
The information provided with regard to faculty financial relationships met my needs for disclosure.
The format of the discussion was relevant and enhanced my competence to treat patients with GBM.
The faculty/speakers were knowledgeable and presented the information clearly.
*
Please use the scale: 1=Poor, 2=Fair, 3=Good, 4=Very Good, 5=Excellent
12345
Michael Lim, MD
David A. Reardon, MD
John H. Sampson, MD, PhD, MBA
*
*

Attestation to time spent on activity:

The Elsevier Office of Continuing Medical Education designates this live activity for a maxiumum of 1.5 AMA PRA Category 1 CreditsTM.

*